来自国际顶尖团队的研究人员针对炭疽致死毒素 (LT)引发MEKs蛋白水解失活、导致ERK/p38/JNK信号通路中断的致命机制，创新性构建了抗蛋白酶解的MEK2 (P10V/A11D)、MEK3 (I27D)和MEK6 (I15D)突变体。转基因小鼠实验证实，这些突变体可维持ERK/p38通路持续激活，显著提升宿主细胞在LT或炭疽杆菌攻击下的存活率，为毒素内化后的靶向治疗开辟新途径。

Anthrax, an infectious disease caused by the bacterium Bacillus anthracis, is often treatable in its early stages. But once ...

University of Pittsburgh researchers discovered that a mix of growth factors can rescue cells from late-stage anthrax damage ...

Anthrax, an infectious disease caused by the bacterium Bacillus anthracis, is often treatable in its early stages. But once ...

Influenza and some other RNA viruses rely on the Raf/MEK/ERK signaling pathway inside human cells to replicate. Atriva’s lead candidate, ATR-002, is a small-molecule inhibitor of MEK ...

Results provide proof-of-concept that ERK pathway reactivation might be an effective, biologically based therapy to prevent anthrax-induced lethality.

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

One major focus of our lab is the study and development of selective inhibitors of the ERK pathway to treat the tumors driven by ERK hyperactivation. Previously we found that activation of ERK output ...

Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors ...